C2B2

AcronymDefinition
C2B2Colorado Center for Biofuels and Biorefining (Boulder, CO)
C2B2Colorado Center for Biofuels and Biorefining (research center of Colorado Renewable Energy Collaboratory)
References in periodicals archive ?
The university is also exploring other drug discovery and wellness programs at its Center for Natural Drug Discovery and Development (CND3) and C2B2, which are both funded by the DOST.
"Banking on the legacy of erythromycin, our (C2B2) labin the University of San Agustin is looking at new antibiotics from actinobacteria, dwelling in the marine sediments.
"We were using a traditional NAS system that struggled to support the huge amounts of input/output demands on the 400 CPUs in our computing infrastructure," said John Lowell Wofford, director of IT services for Columbia University's C2B2. "We knew that we'd soon outgrow that number by at least ten times.
The ConocoPhillips Center for Energy Innovation will occupy a portion of the new wing, and bring under one tool select researchers from two CU Boulder research programs it supports, C2B2 and the Renewable and Sustainable Energy Institute, or RASEI.
The company senior vice president, technology, Stephen Brand, said, 'We are pleased to be launching this promising new research effort in conjunction with C2B2. This agreement with the Collaboratory offers a unique opportunity to combine the technical strengths of the member institutions with ConocoPhillips' spirit of innovation to drive discovery of the next generation of transportation fuels.
In all, 27 members--about 1 0 of which paid $50,000 while those with less than 500 employees paid $10,000--have invested in C2B2 and the opportunity to "sit at the table, helping us direct research and be involved in developments as they happen," Hiller says.
A3B3, B1C1, B2C2, B3C3 (trials presented randomly) C1D1, C2D2, C3D3, D1E1, D2E2, D3E3 Test for emerged relations (trials presented randomly intermixed) Baseline trials A1B1, A2B2, A3B3, B1C1, B2C2, B3C3, C1D1, C2D2, C3D3, D1E1, D2E2, D3E3 Symmetry trials B1A1, B2A2, B3A3, C1B1, C2B2, C3B3, D1C1, D2C2, D3C3, E1D1, E2D2, E3D3 Transitivity trials A1C1, A2C2, A3C3, A1D1, B1D1, A2D2, B2D2, A3D3, B3D3, A1E1, B1E1, C1E1, A2E2, B2E2, C2E2, A3E3, B3E3, C3E3 Equivalence trials C1A1, D1A1, E1A1, C2A2, D2A2, E2A2, C3A3, D3A3, E3A3, D1B1, E1B1, D2B2, E2B2, D3B3, E3B3, E1C1, E2C2, E3C3 Experimental phases % program Number of consequences trials Acquisition of baseline relations (all trial types presented randomly) 1.
They were grouped in three rows C2B2, B1C1, and A1B1 and without labels by participant C2, and in two rows corresponding to Fig.
On the computer: Training and testing of equivalence classes A1, B1, C1 and A2, B2, C2 A one-to-many conditional discrimination procedure was used, which comprised three phases: Phase 1 (train A-B; blocks of eight trials, four trials each of A1-B1 and A2-B2); Phase 2 (train A-C; blocks of eight trials, four trials each of A1-C1 and A2-C2); and Phase 3 (test B-C, C-B; blocks of eight trials, two trials each of B1C1, B2C2, C1B1, C2B2).
The compound stimuli were B1A1, B2A2, C1B1, and C2B2 ("correct compounds") and B1A2, B2A1, C1B2, and C2B1 ("incorrect compounds"; see Table 1).
The trial types involved in tests for symmetry were B1A1, B2A2, B3A3, C1B1, C2B2, and C3B3; for transitivity, A1C1, A2C2, and A3C3; and for equivalence, CIAI, C2A2, and C3A3.
Mixed trials A1B1, A2B2, 0 % 36 34 (trials A3B3, B1C1, presented B2C2, B3C3 randomly) C1D1, C2D2, C3D3, D1E1, D2E2, D3E3 Test for derived relations All trial types Baseline randomly trials intermixed A1B1, A2B2, 0 % 36 34 A3B3, B1C1, B2C2, B3C3 C1D1, C2D2, C3D3, D1E1, D2E2, D3E3 Symmetry trials B1A1, B2A2, 0 % 36 34 B3A3, C1B1, C2B2, C3B3 D1C1, D2C2, D3C3, E1D1, E2D2, E3D3 1 Node trials A1C1, A2C2, A3C3, C1A1, C2A2, C3A3 B1D1, B2D2, 0 % 54 49 B3D3, D1B1, D2B2, D3B3, C1E1, C2E2, C3E3, E1C1, E2C2, E3C3, 2 Node trials A1D1, A2D2, 0 % 36 34 A3D3, D1A1, D2A2, D3A3 B1E1, B2E2, B3E3, E1B1, E2B2, E3B3 3 Node trials A1E1, A2E2, 0 % 18 17 A3E3, E1A1, E2A2, E3A3.